



## CSRC Think Tank: Practical Approaches to Generating Clinical Evidence for the Treatment of Cardiogenic Shock

Washington, DC  
July 24, 2019

### 8:00am – 8:15am Introduction and Purpose of Think Tank Mitchell Krucoff, MD (Duke)

- Introduction to CSRC
- Anatomy of a Think Tank

### 8:15am – 8:30am Summary of CSRC Shock I Marc Samsky, MD (Duke)

### 8:30am – 9:15am Session 1: Plenaries: Unmet needs in treating cardiogenic shock

- Circulatory device perspective **bill o'neil** (Henry Ford)
- Surgical Perspective **Jacob Schroder, MD** (Duke)
- An electro-physiologic device perspective **Bill Abraham, MD** (OSU)
- Regulatory Perspective **TBD** (5 min)

### 9:15am – 11:00am Session 2: Definitions of Cardiogenic Shock

*Moderator: David Morrow, MD MPH (BWH/Harvard)*

- Clinical Perspective: Is there a consensus definition? Do we need one? **Judith Hochman, MD** (NYU Langone) (5 min)
- Advancing Definitions in CHF (HF Collaboratory, ARC-CHF): Relevance to Shock. **Chris O'Connor, MD** (INOVA)
- Clinical Perspective: Deep phenotyping: Staging and grading cardiogenic shock – is this necessary? **Navin Kapur, MD** (Tufts) (5 min)
- Regulatory Perspective: What is an acceptable definition? **TBD** (5 min)

### 9:45am – 10:30: Discussion

10:30am – 10:45am Break

### 10:45am – 11:10am Session 2: Systems based care for patients with cardiogenic shock: Organized Shock Teams and Centers of Excellence

*Moderator: Joaquin Cigarroa, MD (Oregon Health and Sciences)*

- Clinical best practices: Are “Shock Teams” necessary? **Behnam Tehrani, MD** (INOVA) (5 min)
- Clinical Perspective: Can cardiogenic shock care be organized using existing infrastructure? **Alice Jacobs, MD** (Boston University)(5 min)
- Clinical Perspective: What should be considered a “Center of Excellence”? **E. Magnus Ohman, MD** (Duke) (5 min)
- Regulatory Perspective **TBD** (5 min)
- Industry Perspective **TBD** (5 min)

### 11:10am – 12:15pm Discussion

12:15pm – 12:45pm Break/Lunch

### 12:45pm - 1:20pm Session 3: What is the best approach to generating evidence? Registries, trials, both?

*Moderator: Alastair Proudfoot, MBChB, PhD (St. Barts, London)*

- Clinical Perspective: What can we learn from ongoing randomized trials? DangerShock and EuroShock **Holger Thiele, MD** (University of Leipzig)(5 min)
- Clinical Perspective – Registry Based Trials: SAFE-PCI for Women **Connie Hess, MD**(University of Colorado) (5 min)
- Clinical Perspective: What avenues are available to incorporate data acquisition into routine care? **Adam DeVore, MD** (Duke) (5 min)
- Clinical Perspective: Enrollment, Follow Up and End Points – Who should be included? How frequent should we reassess? **Timothy Henry, MD** (Cedars-Sinai) (5 min)
- Statistical Perspective **Andrew Althouse, PhD** (University of Pittsburgh)(5 min)
- Regulatory Perspective **TBD** (5 min)
- Industry Perspective **TBD** (5 min)

1:20pm – 1:30pm Break

### 1:30pm: Open session for discussion and concluding thoughts: Where do we go from here?

*Moderator: Sunil Rao, MD (Duke)*